Karyopharm Therapeutics (KPTI) Scheduled to Post Quarterly Earnings on Tuesday

Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to be announcing its earnings results before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Karyopharm Therapeutics has set its FY 2024 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to analysts’ expectations of $36.07 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Karyopharm Therapeutics Price Performance

KPTI opened at $0.90 on Monday. The firm has a market capitalization of $112.61 million, a price-to-earnings ratio of -0.77 and a beta of 0.16. Karyopharm Therapeutics has a one year low of $0.62 and a one year high of $1.95. The business has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $0.91.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KPTI. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Friday. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Robert W. Baird lowered their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).